At the 2021 annual performance briefing held this afternoon, Tofflon Science And Technology Group Co.Ltd(300171) ( Tofflon Science And Technology Group Co.Ltd(300171) . SZ) executives disclosed to the associated press reporters and investors that during the Shanghai epidemic, the company carried out closed plant management to minimize the adverse impact of the epidemic on the company. At present, the company has sufficient orders on hand, and is actively arranging production capacity according to its own development needs.
The annual report shows that Tofflon Science And Technology Group Co.Ltd(300171) achieved a revenue of 4.192 billion yuan in 2021, a year-on-year increase of 54.83%, a three-year high, a net profit attributable to parent company of 828 million yuan, a year-on-year increase of 78.59%, and a deduction of non attributable net profit of 760 million yuan, a year-on-year increase of 92%.
Tofflon Science And Technology Group Co.Ltd(300171) chairman and general manager Zheng Xiaodong told the financial associated press that in 2021, the company continued to strengthen the layout and expansion of the international market, and the proportion of overseas revenue gradually increased. At the same time, the proportion of material costs, expenses and operating revenue decreased compared with the same period of last year.
The financial Associated Press reporter noted that Tofflon Science And Technology Group Co.Ltd(300171) “bioengineering stand-alone machine and system” project achieved a revenue of 907 million yuan, a year-on-year increase of 305.15%, and its proportion in revenue increased sharply from 8.27% in 2020 to 21.63%.
In response, Tofflon Science And Technology Group Co.Ltd(300171) financial director Xu Zhijun told the associated press that the bioengineering stand-alone and system business is mainly for macromolecular biological drugs and vaccine enterprises, and the main products provided include a full set of products such as bioreactor, chromatography system and wastewater inactivation. With the development of biological medicine and vaccine industry, the clinical demand of new drug enterprises increases rapidly, more new products are approved for listing and cover more and more extensive indications, and pharmaceutical enterprises gradually enter the commercial production stage from the R & D stage. The company’s product demand increases and its income increases year by year.
It is worth mentioning that since Tofflon Science And Technology Group Co.Ltd(300171) is headquartered in Shanghai, the impact of the epidemic has also attracted investors’ attention. Some investors asked whether the epidemic affected the company’s revenue, profits and orders?
Tofflon Science And Technology Group Co.Ltd(300171) Director Tang Huixing did not directly respond to the specific impact of the epidemic on the company’s performance, but said that during the epidemic in Shanghai, the company obeyed the relevant epidemic prevention arrangements of the government and carried out closed management of the plant area. The company actively took Countermeasures under the condition of good epidemic prevention and control, so as to minimize the adverse impact of the epidemic on the company and ensure the company’s production and operation. The company will also continue to pay attention to the epidemic situation, Take different prevention, control and response measures according to different situations.
Recently, Shanghai Tofflon Science And Technology Group Co.Ltd(300171) Medical Equipment Co., Ltd., a subordinate of Tofflon Science And Technology Group Co.Ltd(300171) was listed in the “white list” of the first batch of key operation guarantee in Shanghai. The company told the financial associated press that the inclusion of its subsidiaries in the white list has indeed had a positive impact on enterprises, especially the upstream supporting suppliers of enterprises. Many enterprises have started to resume production on the premise of meeting the requirements of epidemic prevention and control, so as to ensure the normal operation of white list enterprises.
In addition, for the current capacity utilization rate of the company, Tang Huixing told the financial associated press that the company is actively distributing capacity according to its own development needs, and the Jiangsu Dongtai project and Jinshan biopharmaceutical system equipment industrialization project disclosed by the company are under construction.
In February this year, Tofflon Science And Technology Group Co.Ltd(300171) announced that it planned to raise no more than 3.2 billion yuan for the trial production center project of biopharmaceutical equipment industry, Jiangsu biopharmaceutical equipment industrialization base project, Hangzhou life science industrialization base project and supplementary working capital.
Tofflon Science And Technology Group Co.Ltd(300171) Secretary Wang Yan told the associated press that the relevant projects are being promoted in an orderly manner.
Zheng Xiaodong further told investors that the implementation of the fund-raising investment project will effectively improve the company’s R & D technology level in the field of pharmaceutical equipment business, improve the overall production capacity of core equipment, expand the layout of emerging areas of CGT, and create new growth points of performance. It is the technical upgrading of the company’s existing business and the enrichment of products.
